Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus rating of “Hold” from the twenty-three brokerages that are presently covering the company. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $161.86.

A number of analysts have recently issued reports on the company. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price target on the stock in a research note on Monday, April 24th. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 13th. Evercore ISI raised Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a research note on Monday, February 27th. Leerink Swann raised Illumina from a “market perform” rating to an “outperform” rating and set a $195.00 price target on the stock in a research note on Monday, March 20th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $175.00 price target (up from $165.00) on shares of Illumina in a research note on Saturday, April 29th.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of Illumina stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $187.07, for a total value of $300,995.63. Following the sale, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director A Blaine Bowman sold 2,300 shares of Illumina stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $181.61, for a total value of $417,703.00. Following the completion of the sale, the director now owns 18,004 shares in the company, valued at approximately $3,269,706.44. The disclosure for this sale can be found here. Insiders sold 35,521 shares of company stock worth $6,465,772 in the last 90 days. Company insiders own 1.60% of the company’s stock.

Several large investors have recently bought and sold shares of ILMN. Advocacy Wealth Management Services LLC purchased a new stake in Illumina during the first quarter valued at about $102,000. Gemmer Asset Management LLC increased its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Advisory Services Network LLC purchased a new stake in Illumina during the first quarter valued at about $117,000. Stanford Investment Group Inc. increased its stake in Illumina by 5.7% in the fourth quarter. Stanford Investment Group Inc. now owns 1,400 shares of the life sciences company’s stock valued at $179,000 after buying an additional 75 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. increased its stake in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Illumina, Inc. (ILMN) Receives Average Recommendation of “Hold” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/05/22/illumina-inc-ilmn-receives-average-recommendation-of-hold-from-analysts.html.

Illumina (NASDAQ:ILMN) traded down 0.94% during mid-day trading on Monday, reaching $175.35. The company’s stock had a trading volume of 558,495 shares. The company has a market cap of $25.60 billion, a PE ratio of 35.49 and a beta of 0.79. Illumina has a 12-month low of $119.37 and a 12-month high of $189.48. The firm’s 50 day moving average is $178.52 and its 200-day moving average is $156.83.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The company had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. During the same period last year, the company earned $0.71 earnings per share. Illumina’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities analysts anticipate that Illumina will post $3.63 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

12 Month Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.